Figure 10
From: Green nanotechnology of MGF-AuNPs for immunomodulatory intervention in prostate cancer therapy
MGF-AuNPs preferentially accumulate in spleens of SCID mice: (A) Biodistribution of MGF-198AuNPs in normal mice showing selective uptake only in liver and spleen and limited/no uptake in non-target organs; (B) Biodistribution of MGF-AuNPs in prostate tumor bearing SCID mice. Gold concentrations in tumor, liver and spleen measured using neutron activation analysis (NAA)—showing limited uptake in tumors and major uptake in spleen and liver—suggesting targeting of MGF-AuNPs on splenic macrophages.
